Laboratory practice is central to earlier myeloma diagnosis : Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services
© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd..
Treatment advances have greatly improved survival, but myeloma is among the worst of all cancers for delayed diagnosis, causing serious morbidities and early deaths. This delay is largely because the symptom profile of myeloma has very low specificity, and in primary care, myeloma is rare. However, initiating the journey to diagnosis simply requires considering myeloma and sending blood to test for monoclonal immunoglobulin. Laboratory tests reliably detect monoclonal immunoglobulin, which is present in 99% of myeloma cases, so why do health care systems have such a problem with delayed diagnosis? The Myeloma UK early diagnosis programme has brought together diverse expertise to investigate this problem, and this article was prepared by the programme's working group for laboratory best practice. It reviews evidence for test requesting, analysis and reporting, for which there is large variation in practice across the United Kingdom. It presents a 'GP Myeloma diagnostic tool' and how it can be integrated into laboratory practice alongside a laboratory best practice tool. It proposes improved requesting and integration with haematology services for reporting and interpretation. Here the laboratory has a central role in creating efficient and cost-effective pathways for appropriate and timely bone marrow examination for myeloma diagnosis.
| Errataetall: |
CommentIn: Br J Haematol. 2024 Feb;204(2):393-394. - PMID 38168005 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:204 |
|---|---|
| Enthalten in: |
British journal of haematology - 204(2024), 2 vom: 29. Feb., Seite 476-486 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Drayson, Mark [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Earlier diagnosis |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 06.03.2024 published: Print-Electronic CommentIn: Br J Haematol. 2024 Feb;204(2):393-394. - PMID 38168005 Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.19224 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366593854 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366593854 | ||
| 003 | DE-627 | ||
| 005 | 20240306232655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.19224 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM366593854 | ||
| 035 | |a (NLM)38168756 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Drayson, Mark |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Laboratory practice is central to earlier myeloma diagnosis |b Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Br J Haematol. 2024 Feb;204(2):393-394. - PMID 38168005 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Treatment advances have greatly improved survival, but myeloma is among the worst of all cancers for delayed diagnosis, causing serious morbidities and early deaths. This delay is largely because the symptom profile of myeloma has very low specificity, and in primary care, myeloma is rare. However, initiating the journey to diagnosis simply requires considering myeloma and sending blood to test for monoclonal immunoglobulin. Laboratory tests reliably detect monoclonal immunoglobulin, which is present in 99% of myeloma cases, so why do health care systems have such a problem with delayed diagnosis? The Myeloma UK early diagnosis programme has brought together diverse expertise to investigate this problem, and this article was prepared by the programme's working group for laboratory best practice. It reviews evidence for test requesting, analysis and reporting, for which there is large variation in practice across the United Kingdom. It presents a 'GP Myeloma diagnostic tool' and how it can be integrated into laboratory practice alongside a laboratory best practice tool. It proposes improved requesting and integration with haematology services for reporting and interpretation. Here the laboratory has a central role in creating efficient and cost-effective pathways for appropriate and timely bone marrow examination for myeloma diagnosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a earlier diagnosis | |
| 650 | 4 | |a laboratory practice | |
| 650 | 4 | |a myeloma | |
| 700 | 1 | |a Jennis, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Laketic-Ljubojevic, Ira |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Dina |e verfasserin |4 aut | |
| 700 | 1 | |a Pratt, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Renwick, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Wheeler, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Sheldon, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Sadler, Ross |e verfasserin |4 aut | |
| 700 | 1 | |a Stapleton, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Willis, Fenella |e verfasserin |4 aut | |
| 700 | 1 | |a Whiston, Mairi |e verfasserin |4 aut | |
| 700 | 0 | |a for Myeloma UK working group for laboratory best practice |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 204(2024), 2 vom: 29. Feb., Seite 476-486 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:204 |g year:2024 |g number:2 |g day:29 |g month:02 |g pages:476-486 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.19224 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 204 |j 2024 |e 2 |b 29 |c 02 |h 476-486 | ||